Table 2.
Base-case results of strategies for refractory or recurrent Clostridioides difficile infection.
| Category | Cost | Incr cost | QALY | Incr QALY | ICER | NMB |
|---|---|---|---|---|---|---|
| FMT vs. vancomycin | ||||||
| FMT (Overall) | 54,713.28 | 25,215.20 | 0.9363 | 0.0229 | 1,101,971.98 | 41,879.968 |
| Vancomycin (Overall) | 29,498.08 | - | 0.9134 | - | - | - |
| FMT (IBD) | 80,643.52 | 43,818.52 | 0.9170 | 0.0239 | 1,833,719.14 | 26206.568 |
| Vancomycin (IBD) | 36,825.00 | - | 0.8931 | - | - | - |
| FMT vs. fidaxomicin | ||||||
| FMT (Overall) | 54,713.28 | 6,512.67 | 0.9363 | 0.0115 | 567,133.45 | 27,181.41 |
| Fidaxomicin (Overall) | 48,200.61 | - | 0.9248 | - | - | |
| FMT (IBD) | 80,643.52 | 22,716.11 | 0.9170 | 0.0018 | 12,360,976.83 | −17,442.254 |
| Fidaxomicin (IBD) | 57,927.41 | - | 0.9152 | - | - | - |
FMT, fecal microbiota transplantation; IBD, inflammatory bowel disease; Incr, incremental; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; NMB, Net monetary benefit.
All costs are expressed in New Taiwan Dollars (NT$).